Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC

MLA

Louise M. Nott, et al. “Multicenter Randomized, Open-Label Phase II Trial of Sequential Erlotinib and Gemcitabine Compared with Gemcitabine Monotherapy as First-Line Therapy in Elderly or ECOG PS Two Patients with Advanced NSCLC.” Asia-Pacific Journal of Clinical Oncology, vol. 11, Feb. 2014, pp. 4–14. EBSCOhost, https://doi.org/10.1111/ajco.12178.

APA

Louise M. Nott, Alexander Dobrovic, Benjamin Solomon, Phillip R Clingan, E Abdi, Michael Michael, Hongdo Do, Stephen Clarke, Peter Button, Daniel Gregory, Shane White, & Allan Solomon Zimet. (2014). Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC. Asia-Pacific Journal of Clinical Oncology, 11, 4–14. https://doi.org/10.1111/ajco.12178

Chicago

Louise M. Nott, Alexander Dobrovic, Benjamin Solomon, Phillip R Clingan, E Abdi, Michael Michael, Hongdo Do, et al. 2014. “Multicenter Randomized, Open-Label Phase II Trial of Sequential Erlotinib and Gemcitabine Compared with Gemcitabine Monotherapy as First-Line Therapy in Elderly or ECOG PS Two Patients with Advanced NSCLC.” Asia-Pacific Journal of Clinical Oncology 11 (February): 4–14. doi:10.1111/ajco.12178.